Fredun Pharmaceuticals Ltd

₹ 2,311 0.59%

09 Jun - close price

About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products^[1]

Key Points

Business Overview:{# https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ad9e590-baf1-43e5-a921-d0d5a2e4d356.pdf#page=2#}
The company is a diversified healthcare company engaged in pharmaceuticals, nutraceuticals, cosmeceuticals, dietary supplements, and animal healthcare products. Its pharmaceutical portfolio spans multiple therapeutic areas, including antihypertensives, antidiabetics, antiretrovirals (ARVs), and narcotics.

Website BSE

Market Cap ₹ 1,274 Cr.
Current Price ₹ 2,311
High / Low ₹ 2,620 / 720
Stock P/E 38.4
Book Value ₹ 509
Dividend Yield 0.03 %
ROCE 21.5 %
ROE 15.8 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 75.2% CAGR over last 5 years
Debtor days have improved from 87.8 to 52.9 days.
Promoter holding has increased by 1.51% over last quarter.
Company's median sales growth is 28.6% of last 10 years

Cons

Promoter holding has decreased over last 3 years: -5.58%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	80	62	82	87	118	79	107	103	167	120	145	161	213
	68	54	72	76	107	68	93	89	150	103	123	135	184
Operating Profit	12	8	10	11	11	10	14	13	17	17	22	26	29
OPM %	15%	12%	12%	12%	9%	13%	13%	13%	10%	14%	15%	16%	14%
	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest	4	3	3	4	4	4	5	5	8	7	8	11	14
Depreciation	1	1	1	1	1	1	1	1	1	1	2	2	3
Profit before tax	8	4	6	6	6	6	8	7	8	9	13	14	12
Tax %	51%	41%	32%	27%	13%	25%	44%	25%	12%	25%	25%	25%	4%
	4	2	4	4	5	4	4	5	7	7	10	10	11
EPS in Rs	8.58	5.24	8.41	8.98	10.76	8.75	9.04	11.29	14.97	14.34	20.61	19.53	20.23
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	25	42	57	60	97	113	134	222	275	348	454	639
	24	38	53	54	87	104	126	208	247	310	401	544
Operating Profit	2	4	3	6	10	8	8	14	28	38	53	95
OPM %	7%	9%	6%	10%	11%	7%	6%	6%	10%	11%	12%	15%
	0	1	2	0	0	1	1	2	2	1	2	0
Interest	1	2	2	2	3	4	4	5	9	14	22	39
Depreciation	1	1	1	1	1	2	2	2	3	4	4	8
Profit before tax	1	2	2	3	6	2	3	9	18	21	28	48
Tax %	52%	42%	36%	34%	28%	24%	37%	26%	38%	27%	26%	30%
	0	1	1	2	4	2	2	6	11	16	21	33
EPS in Rs	1.11	4.55	6.08	5.11	11.18	4.76	5.04	14.30	23.85	33.22	44.07	60.68
Dividend Payout %	0%	13%	10%	12%	6%	14%	14%	5%	3%	2%	2%	1%

Compounded Sales Growth
10 Years:	31%
5 Years:	37%
3 Years:	33%
TTM:	41%

Compounded Profit Growth
10 Years:	40%
5 Years:	75%
3 Years:	45%
TTM:	60%

Stock Price CAGR
10 Years:	62%
5 Years:	40%
3 Years:	40%
1 Year:	220%

Return on Equity
10 Years:	14%
5 Years:	15%
3 Years:	15%
Last Year:	16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	2	2	2	3	4	4	4	4	5	5	5	5
Reserves	0	1	2	19	35	37	39	64	92	117	137	273
	9	16	21	10	19	35	40	53	87	106	166	222
	11	24	30	47	47	65	79	66	74	81	179	141
Total Liabilities	23	43	56	79	105	141	162	187	257	308	487	642
	8	15	16	16	31	31	30	32	39	47	53	118
CWIP	1	0	4	11	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	0	1	2	2
	14	29	36	52	74	110	131	155	218	260	433	522
Total Assets	23	43	56	79	105	141	162	187	257	308	487	642

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	3	4	17	1	-11	0	-2	-14	-0	-29	120
	-3	-6	-7	-8	-5	-1	-1	-4	-9	-8	-6	-74
	1	3	3	-8	4	14	-1	7	25	6	38	18
Net Cash Flow	0	1	-1	1	0	2	-2	1	1	-2	3	65
Free Cash Flow	-1	-3	-3	9	-4	-12	-1	-7	-24	-8	-35	46
CFO/OP	108%	85%	117%	303%	8%	-128%	2%	-17%	-52%	-1%	-55%	126%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	75	98	131	94	67	126	112	148	46	68	142	53
Inventory Days	102	140	68	170	249	227	242	96	264	246	267	217
Days Payable	167	221	224	360	205	208	215	101	104	88	161	70
Cash Conversion Cycle	11	17	-24	-96	110	145	139	144	205	225	248	199
Working Capital Days	-54	-44	-39	42	66	65	116	126	97	92	76	78
ROCE %	14%	25%	18%	16%	21%	10%	10%	13%	18%	17%	19%	21%

Insights

In beta

Mar 2007

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Daily Compression Capacity (Tablets)
Million Units

	x.xx	xx.xx	x.xx	xx.xx	x.xx	xx.xx	xx.xx		x.xx	xx.xx	x.xx
	x,xxx	x,xxx	x,xxx	x,xxx	xx,xxx	xx,xxx	xx,xxx		xx,xxx	xx,xxx	x,xxx
	xx	xx		xx	xx	xx	xx	xx	xx	xx	xx
xx	xxx	xxx		xxx	xxx			xxx	x,xxx	xxx	xxx
					xxx	xxx		xxx	x,xxx	x,xxx	x,xxx
					xx,xxx	xx,xxx			xxx,xxx	xxx,xxx	xx,xxx
							x	xx	xx	xxx

Please log in to see hidden values.

Daily Granulation Capacity (Tablets)
Kgs

Number of International Markets Present
Countries

Number of Registered Products Globally
Count

Products Under Registration Globally
Count

Daily Topicals Capacity
Tubes

Pet Care (Freossi) Product Portfolio
SKUs

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Apr 2026
	49.31%	49.16%	49.17%	49.17%	48.93%	48.93%	48.93%	48.93%	48.93%	43.06%	44.17%	44.57%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.46%	1.06%	1.06%
	1.60%	1.60%	1.60%	1.60%	1.59%	1.59%	1.59%	1.59%	1.61%	3.48%	2.83%	2.81%
	49.08%	49.24%	49.24%	49.23%	49.47%	49.47%	49.47%	49.49%	49.46%	53.00%	51.94%	51.56%
No. of Shareholders	6,313	6,837	7,507	7,511	8,018	8,121	7,976	7,906	8,120	8,765	8,338	8,308

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Apr 2026
	74.44%	54.04%	52.04%	52.04%	52.04%	51.27%	50.15%	49.17%	48.93%	44.17%	44.57%
	0.00%	0.00%	1.68%	1.23%	0.00%	0.00%	0.00%	0.00%	0.00%	1.06%	1.06%
	3.19%	2.19%	1.88%	1.88%	1.88%	1.69%	1.65%	1.60%	1.59%	2.83%	2.81%
	22.37%	43.77%	44.40%	44.85%	46.08%	47.04%	48.20%	49.24%	49.47%	51.94%	51.56%
No. of Shareholders	509	562	1,046	1,478	1,992	3,620	4,521	7,507	7,976	8,338	8,308

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Feb 2026
Transcript
PPT
Nov 2025
Transcript
PPT
REC
Aug 2025
Transcript
PPT
REC
Jun 2025

Transcript

AI Summary
PPT
Jun 2025

Transcript

AI Summary
PPT
Feb 2023

Transcript

AI Summary
PPT
Jun 2019

Transcript

AI Summary
PPT